A structured readiness assessment covering documentation, classification, local representation, and dossier quality gates before filing with COFEPRIS for medical device registration in Mexico.
This checklist is designed for regulatory affairs and business development teams preparing a COFEPRIS application for the sanitary registration of medical devices in Mexico. Work through each section in order. Items are sequenced to reflect the actual workflow completing earlier sections prevents rework in later stages.
Important: This checklist covers general readiness for most medical device registrations. Requirements may vary by product classification (Class I, II, III), risk profile, and whether the product requires laboratory testing. Consult with a regulatory specialist for pathway-specific guidance.
Monthly insights on COFEPRIS, market access, and compliance changes.
Class I, II, or III, in accordance with COFEPRIS classification rules.
Confirmation of the registration pathway to be followed:
Mexico-based individual or entity authorized to act before COFEPRIS on behalf of the foreign manufacturer.
Formal agreement defining scope of authority, responsibilities, confidentiality, and termination conditions.
Legal document authorizing the representative to file and manage regulatory submissions with COFEPRIS.
Letter from the legal manufacturer authorizing the representative and/or distributor to act in Mexico.
Certificate from the country of origin confirming the product is legally marketed, issued by the relevant regulatory authority.
Good Manufacturing Practice Certificate issued by the health authority of the country of origin or its equivalent document.
Copies of approvals from FDA, Health Canada, CE marking, etc.
Translated and reviewed by a bilingual regulatory reviewer to ensure consistency with the technical file.
All product labels fully translated into Spanish, with verification to ensure consistency with the technical file and full compliance with the applicable NOM.
Determine the laboratory tests required based on the product’s category and risk classification.
Description of the primary and, if applicable, secondary packaging, specifying the materials and dimensional specifications.
Evidence supporting the claimed shelf life and storage conditions, particularly for products sensitive to environmental factors.
If the device contacts the patient, appropriate biocompatibility testing per ISO 10993 series or equivalent.
Documented approach: clinical investigation data, literature review, performance testing, or equivalence-based justification.
Structured index following COFEPRIS format requirements, with clear section numbering and document references.
International authentication (apostille) for foreign legal documents as required by Mexican regulatory process.
Confirmed COFEPRIS registration fee amount and payment mechanism (federal tax payment format).
Full pre-submission review by the regulatory team confirming completeness, consistency, and cross-reference accuracy.
This checklist is designed for regulatory affairs professionals, business development leaders, and quality managers at companies preparing to file a medical device, diagnostic, or pharmaceutical product with COFEPRIS. It is especially useful for foreign manufacturers entering the Mexican market for the first time, where unfamiliarity with local requirements creates the highest risk of delays and rework.
No. This checklist is a structured readiness assessment that helps teams identify gaps before engaging with COFEPRIS. It does not replace professional regulatory consulting. Product-specific requirements vary by classification, risk profile, and regulatory pathway. A qualified regulatory affairs specialist should review the complete dossier before submission to ensure compliance with current COFEPRIS guidelines.
Completion time varies significantly by product type and organizational readiness. Companies with existing CE marking or FDA clearance and well-organized technical files can often complete the checklist in 4 to 6 weeks. Teams building documentation from scratch or establishing local representation for the first time should expect 8 to 12 weeks. The most common bottlenecks are local legal representation agreements, Spanish labeling translations, and clinical evidence compilation.
Yes. The majority of checklist items — classification, local representation, labeling, submission assembly, and lifecycle governance — apply to both medical devices and pharmaceutical products. However, pharmaceutical registrations require additional documentation including bioequivalence or bioavailability studies, detailed stability data under ICH guidelines, and manufacturing process validation specific to drug production. Teams registering pharmaceutical products should treat this checklist as a foundation and supplement it with pharma-specific regulatory requirements.
Monthly regulatory updates, market access insights, and COFEPRIS process changes curated for medtech and pharma decision-makers.
